Pharmacokinetics (PK) and exposure-response (ER) of rilotumumab (Rmab) in patients (pts) with small-cell lung cancer (SCLC).
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Yilong Zhang, Jenny Zheng, Rui Tang, Elwyn Loh, Sarita Dubey, Min Zhu
Institutions: Amgen (United States), Pfizer (United States)
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2760414622